NasdaqCM:IMNMBiotechs
Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise
Immunome (IMNM) just delivered a big one two for investors, first unveiling strong Phase 3 RINGSIDE data for varegacestat in desmoid tumors, then swiftly raising about $400 million through a follow on stock offering.
See our latest analysis for Immunome.
Those blockbuster Phase 3 results and the follow on raise have not gone unnoticed, with the share price climbing to $22.33 and delivering a 90 day share price return of about 120 percent, while the three year total shareholder return is...